Clinical trial
Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory…
NCT00251368 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00251368 |
|---|---|
| Title | Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory Leukemia |
| Official title | Multicenter Study of 9-AC in Refractory Leukemia |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Brigham and Women's Hospital Beth Israel Deaconess Medical Center Massachusetts General Hospital |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia, Myelocytic, Acute, Acute Lymphocytic Leukemia |
| Intervention type | Drug |
| Interventions | 9-Aminocamptothecin (9-AC) |
| Enrollment | 52 |
| Start date | Jan 1, 1995 |
| Primary completion | Sep 1, 2007 |
| Completion | Sep 1, 2007 |
| First posted | Nov 10, 2005 |
| Last update posted | Mar 10, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: